A method of treating cancer in a subject in need thereof, in particular microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) cancer, the method comprising administering to the subject a therapeutically effective amount of a WRN inhibitor in combination with a therapeutically effective amount of at least one chemotherapy agent selected from gemcitabine, camptothecin, irinotecan (Camptosar®), docetaxel (Taxotere®), doxorubicin (e.g. doxorubicin hydrochloride) (Adriamycin®, Rubex®), 5-fluorouracil (Adrucil®, Efudex®), capecitabine (Xeloda®), etoposide (Vepesid®), epirubicin (Ellence®, Pharmorubicin®), oxaliplatin (Eloxatin®), mitomycin (e.g. mitomycin A, mitomycin B or mitomycin C, particularly mitomycin C), cisplatin (Platinol®), carboplatin (Paraplatin®), bleomycin and paclitaxel (Taxol®). In particular, the chemotherapy agent is selected from irinotecan (Camptosar®), 5-fluorouracil (Adrucil®, Efudex®), epirubicin (Ellence®, Pharmorubicin®), doxorubicin (e.g. doxorubicin hydrochloride) (Adriamycin®, Rubex®), gemcitabine, camptothecin and mitomycin C.